Fabre-Kramer Pharmaceuticals

Fabre-Kramer Pharmaceuticals is a pharmaceutical company that specializes in the development of psychotropic drugs. Products in their current development pipeline include gepirone and FKB01MD for major depression, gepirone and FKW00GA for social anxiety disorder,[1] gepirone for hypoactive sexual desire disorder, FKF02SC for schizophrenia, and FKK01PD for Parkinson's disease.[2]

Fabre-Kramer Pharmaceuticals
TypeS Corporation
IndustryPharmaceuticals
Founded1992
HeadquartersHouston, Texas
Key people
Stephen Kramer (CEO) Ed Koehler (Executive Vice President, CFO)
ProductsTravivo (Gepirone ER), FKB01MD, FKW00GA, FKF02SC, FKK01PD
Websitewww.fabrekramer.com

The company has also conducted clinical studies on a gepirone extended release formulation for major depression.[3][4][5]

In 2007, Fabre-Kramer Pharmaceuticals along with GlaxoSmithKline (GSK) received a 'not approvable' letter from the US Food and Drug Administration, for a gepirone extended release drug, an antidepressant treatment for adults.[6]

References
  1. "Pipeline – Fabre-Kramer Pharmaceuticals, Inc". Archived from the original on March 30, 2023. Retrieved 2023-03-30.
  2. "Product Pipeline". Fabre Kramer Pharmaceuticals. Archived from the original on 2011-11-11. Retrieved 2011-10-16.
  3. Fabre LF, Smith LC (August 2011). "The Effect of Major Depression on Sexual Function in Women". J Sex Med. 9 (1): 231–9. doi:10.1111/j.1743-6109.2011.02445.x. PMID 21883948.
  4. Fabre LF, Smith LC, DeRogatis LR (September 2011). "Gepirone-ER treatment of low sexual desire associated with depression in women as measured by the DeRogatis Inventory of Sexual Function (DISF) fantasy/cognition (desire) domain--a post hoc analysis". J Sex Med. 8 (9): 2569–81. doi:10.1111/j.1743-6109.2011.02330.x. PMID 21707926.
  5. Fabre LF, Brown CS, Smith LC, Derogatis LR (May 2011). "Gepirone-ER treatment of hypoactive sexual desire disorder (HSDD) associated with depression in women". J Sex Med. 8 (5): 1411–9. doi:10.1111/j.1743-6109.2011.02216.x. PMID 21324094.
  6. Lewcock, Anna (November 5, 2007). "GSK, Fabre-Kramer lose out on antidepressant". outsourcing-pharma.com. Archived from the original on September 10, 2023. Retrieved 2020-05-11.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.